Timothy E. Morris

Timothy E. Morris joined Humanetics Corporation in December 2025 as Chief Operating Officer. Mr. Morris was appointed to the Board of Directors in October 2021 and continues to serve in that capacity. Mr. Morris has 36 years of professional finance and accounting experience, including 22 years as Chief Financial Officer with public biotechnology companies (HGEN, IOVA, ACRX, VVUS, QCOR). During his career he has raised over $2 billion in equity and convertible securities for seven companies, including four offerings for IOVA with over $1 billion in proceeds. Previously he served as the COO & CFO of Humanigen Inc. (HGEN) where he was responsible for CMC activities as part of Operation Warp Speed. Prior to Humanigen, Mr. Morris was CFO at Iovance where he oversaw an increase in market cap from $550 million to $4.2 billion (7x increase). In addition, he served as the financial lead for Iovance’s state of the art $85 million cell therapy manufacturing facility in Philadelphia. Mr. Morris has extensive deal experience with over 100 transactions and combined value over $5 billion. Mr. Morris has been part of executive teams that were successful in the approval of 3 NDAs and 1 MAA. Mr. Morris currently serves as a Non-Executive Director for DBV Technologies S.A. (Nasdaq: DBVT, Euronext: DBV – ISIN: FR0010417345), and Aquestive Therapeutics (Nasdaq: AQST)He is a Venture Partner at LongeVC, is a CPA (inactive) and started his career from Chico State with Ernst & Young in Silicon Valley.